NESS ZIONA, Israel, September 30, 2020 — Mapi Pharma Ltd., a privately held, fully integrated, late clinical stage biopharmaceutical company today greets its partner, Zhejiang Jingxin Pharmaceutical Co Ltd.
To our friends and partners at Jingxin Pharma,
On behalf of myself and Mapi Group of Companies I would like to congratulate Jingxin on your 30th anniversary and wish you the best of luck for the future and continued excellent collaboration.
Our companies have a strong partnership that is based on trust, shared values, equity investments, R&D collaborations and the advancement of medicine. We share a vision for the co-development of important products for the Chinese Market that will be produced and marketed by Jingxin for the indications such as schizophrenia, diabetes, and other diseases where long-acting Depot injections can help patients. We also see the possibility of future expansion to include new technologies such as exosomes.
On this special occasion we wish Jingxin continued success to the benefit of all stake holders and are looking forward to taking our partnership to new heights.
Ehud Marom
敬京新药业我的朋友和合作伙伴们，
我谨代表本人和Mapi集团公司祝贺京新药业成立30周年，并祝京新药业未来发展顺利，与我们合作愉快。
我们双方基于信任，共同的价值观，股权投资，研发合作和医学的进步形成了强有力的伙伴关系。我们的愿景是共同开发对中国市场非常重要的产品，这些产品主要是能有效帮助患者的长效注射剂，治疗精神分裂症，糖尿病等疾病。这些产品会由京新药业生产并在中国市场销售。我们展望未来，将开发出更多的新技术，如外泌体。
在这个特殊的时刻，我们祝愿京新药业不断取得成功，造福于所有的股东，并期待我们的合作达到新的高度。
Ehud Marom
About Mapi Pharma
Mapi is a clinical stage pharmaceutical company, engaged in the development of high barrier-to-entry and high added-value life cycle management (“LCM”) products that target large markets and generic drugs that include complex active pharmaceutical ingredients (“APIs”) and formulations. The GA Depot injection, administered once every four weeks, is the first in a series of depot long-acting injections in the company’s pipeline, for the treatment of MS. The product is a LCM version of Copaxone®, which requires injections daily or every other day. Mapi Pharma partnered with Mylan N.V. (NASDAQ: MYL) for GA Depot in an agreement under which Mylan was granted an exclusive license to commercialize the GA Depot injection product for relapsing forms of multiple sclerosis. Mapi is built on strong chemical and pharmaceutical R&D capabilities, a deep understanding of the global market and of regulatory needs. Mapi is headquartered in Israel, with R&D facilities in Israel and China, an API production facility in the Neot-Hovav Eco Industrial Park and an aseptic manufacturing and a Fill & Finish facility for injectable Finished Dosage Forms in Jerusalem. Mapi has a strong IP position, filing numerous patent applications for APIs and formulations. Mapi Pharma was founded by Ehud Marom who serves as Chairman & CEO of Mapi Pharma and Stem Cell Medicine. For more information, please visit: www.mapi-pharma.com.
Download PDF